Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,505
  • Shares Outstanding, K 11,340
  • Annual Sales, $ 40 K
  • Annual Income, $ -7,020 K
  • 36-Month Beta 2.73
  • Price/Sales 533.33
  • Price/Cash Flow N/A
  • Price/Book 3.15

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.70 +1.18%
on 05/24/18
1.85 -7.03%
on 05/08/18
-0.11 (-6.01%)
since 04/24/18
3-Month
1.55 +10.97%
on 02/26/18
3.09 -44.34%
on 04/03/18
+0.10 (+6.17%)
since 02/23/18
52-Week
1.53 +12.05%
on 02/16/18
5.85 -70.60%
on 10/10/17
-2.38 (-58.05%)
since 05/24/17

Most Recent Stories

More News
Bio-Path Holdings Reports First Quarter 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Stock Monitor: Bio-Path Holdings Post Earnings Reporting

ARDM : 1.40 (+4.48%)
BPTH : 1.72 (-1.15%)
Bio-Path Leukemia Combo Study Shows Positive Early Data

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.

LGND : 189.42 (-0.69%)
ENTA : 97.68 (+0.06%)
REGN : 294.61 (-0.24%)
BPTH : 1.72 (-1.15%)
Bio-Path Holdings Reports Full Year 2017 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 3, 2018 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 3, 2018 at 8:30 AM Eastern Time.

BPTH : 1.72 (-1.15%)
Bio-Path Holdings Announces Publication in The Lancet Haematology

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilizeantisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 1.72 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BPTH with:

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

2nd Resistance Point 1.81
1st Resistance Point 1.77
Last Price 1.72
1st Support Level 1.69
2nd Support Level 1.65

See More

52-Week High 5.85
Fibonacci 61.8% 4.20
Fibonacci 50% 3.69
Fibonacci 38.2% 3.18
Last Price 1.72
52-Week Low 1.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar